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Abstract 41 
Context – Deletion of the death receptor Fas (CD95) in adipocytes of mice is associated with 42 
improved insulin sensitivity and reduced adipose tissue (AT) inflammation.  43 
Objective - Here we investigate the relationship of AT Fas with human obesity.  44 
Design and Methods – In paired samples of omental and subcutaneous (SC) AT from 256 lean and 45 
obese (including insulin sensitive (IS) and insulin resistant (IR) subgroups, n=60) participants, we 46 
investigated whether Fas and Fas-ligand (FasL) mRNA expression is fat depot-specific, altered in 47 
obesity and related to measures of AT inflammation and insulin sensitivity. In addition, AT Fas 48 
mRNA expression was measured in 16 obese patients after significant weight loss of 45±6.3kg in the 49 
context of a two-step bariatric surgery strategy. 50 
Results – Fas and FasL are significantly higher expressed in omental compared to SC AT. Fas 51 
expression correlates with BMI (OM, r²=0.44, SC, r²=0.14), AT macrophage infiltration (OM, 52 
r²=0.36, SC, r²=0.16) and glucose infusion rate in euglycemic-hyperinsulinemic clamps (OM, 53 
r²=0.17, SC, r²=0.13) (p<0.05 for all). FasL expression most strongly correlates with adipocyte size 54 
(OM, r²=0.32, SC, r²=0.17) and AT macrophage infiltration (OM, r²=0.46, SC, r²=0.02). IS had 55 
significantly lower Fas and FasL expression than IR obese individuals. Significant weight loss 12 56 
months after gastric sleeve resection is associated with a significantly reduced Fas expression in 57 
omental and SC fat depots. 58 
Conclusions –Independently of body weight, increased Fas expression may contribute to impaired 59 
insulin sensitivity and AT dysfunction in obesity. Moreover, significant weight loss reduces Fas 60 
expression in omental and SC fat depots.   61 
 62 
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Introduction 63 
The majority of patients with obesity has impaired adipose tissue (AT) function which is 64 
characterized by adipocyte hypertrophy, hypoxia, a variety of stresses and inflammatory processes 65 
within adipose tissue (1). Increased number of macrophages infiltrating adipose tissue (2-4), 66 
activation of stress kinases (5), higher expression of autophagy markers (6) as well as increased 67 
adipocyte apoptosis (7, 8) has been reported in human obesity. We and others have recently shown 68 
that inflammation of visceral adipose tissue may contribute to impaired whole body insulin 69 
sensitivity in patients with obesity (9, 10). Moreover, adipocyte apoptosis is increased in AT from 70 
both mice with diet-induced obesity and obese humans (7). In mice, genetic inactivation of Bid, a key 71 
pro-apoptotic molecule, markedly reduced adipocyte apoptosis prevented AT macrophage 72 
infiltration, and protected against the development of systemic insulin resistance suggesting that 73 
adipocyte apoptosis is a key initial event that contributes to macrophage infiltration into adipose 74 
tissue and insulin resistance associated with obesity in both mice and humans (7). 75 
The death receptor Fas (CD95), a member of the TNF receptor family, plays a key role in 76 
promoting programmed cell death (apoptosis) and is activated by its ligand Fas-ligand (FasL). FasL 77 
is a type II membrane protein that belongs to the TNF family. Membrane-bound human FasL is 78 
converted to a soluble form by a matrix metalloproteinase-like enzyme (11). FasL is predominantly 79 
expressed in activated T cells, whereas Fas is expressed in various tissues (11). 80 
Moreover, there is increasing evidence that Fas activation can stimulate inflammatory 81 
pathways in several tissues (11). Accordingly, the secretion of pro-inflammatory cytokines such as 82 
IL-1β, IL-6 and MCP-1 was increased after Fas activation (12), rendering it a potential key 83 
component of the inflammatory response. We have recently shown that adipocyte specific deletion of 84 
Fas improved insulin sensitivity and reduced hepatic steatosis as well as adipose tissue (AT) 85 
inflammation in high fat diet-fed mice (13). Interestingly, Fas activation in adipocytes not only 86 
stimulated the production of proinflammatory cytokines, but also interfered with insulin-stimulated 87 
glucose uptake and induced basal lipolysis suggesting a role of Fas in adipocyte function (14, 15). In 88 
the present study, we tested the hypothesis that Fas and FasL expression in omental and 89 
subcutaneous AT are related to obesity, AT inflammation and insulin sensitivity in paired samples of 90 
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omental and SC AT from 256 subjects with a wide range of obesity, body fat distribution, insulin 91 
sensitivity, and glucose tolerance in the context of a cross-sectional study. In addition, we asked 92 
whether significant weight loss after bariatric surgery changes AT expression of Fas.  93 
 94 
Materials and Methods  95 
 96 
Subjects 97 
We included three different cohorts with a total number of 272 individuals in our study of 98 
Fas and FasL AT mRNA expression. We investigated Fas and FasL mRNA expression in paired 99 
omental and SC adipose tissue samples obtained from 196 extensively characterized Caucasian 100 
overweight (n=32), obese (n=108) and lean (n=56) men (n=74) and women (n=122) who underwent 101 
open abdominal surgery for elective cholecystectomy or explorative laparotomy as described 102 
previously (5, 6). With oral glucose tolerance tests, we identified individuals with type 2 diabetes 103 
(T2D) (n=67) or normal glucose tolerance (NGT) (n=129). Adipose tissue was either analyzed as a 104 
whole (immediately frozen in liquid nitrogen after explantation) (n=196) or after separation into 105 
isolated adipocytes and cells of the stromal vascular fraction (SVF) from omental and SC fat depots 106 
(lean, n=15; obese n=15; NGT, n=15; T2D, n=15) using previously described methods (16). 107 
The second cohort consists of 60 obese individuals (BMI = 45±1.3 kg/m²), which have been 108 
matched for age, gender, BMI and body fat mass into either insulin sensitive (IS) or insulin resistant 109 
(IR) obesity based on the glucose infusion rate (GIR) in euglycemic-hyperinsulinemic clamp (IS, 110 
GIR>70µmol/kg/min; IR, GIR<60µmol/kg/min). The phenotypic characteristics of the latter cohort 111 
have been extensively described (9). Measurement of body fat content, abdominal visceral and SC fat 112 
area, parameters of glucose metabolism, insulin sensitivity as well as analyses of circulating 113 
parameters was performed as described (5, 6, 9).  114 
A third cohort, 16 Caucasian morbidly obese patients (11 women, 5 men) without type 2 115 
diabetes participated in a prospective weight loss study consisting of two bariatric procedures (Table 116 
1). At baseline, patients underwent a sleeve gastrectomy and after ~12 months an elective second-117 
step Roux-en-Y- gastric bypass surgery was performed. Collection of subcutaneous and omental fat 118 
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biopsies was performed both at the time of sleeve gastrectomy and approximately 12 months later 119 
during the Roux-en-Y bypass surgery. Patients with malignant diseases or acute or chronic 120 
inflammatory diseases were excluded from the study in all subcohorts. All subjects had a stable 121 
weight, defined as the absence of fluctuations of >2% of body weight for at least 3 months before 122 
surgery. All study protocols have been approved by the Ethics committee of the University of 123 
Leipzig. All participants gave written informed consent before taking part in the study.  124 
 125 
Measurement of body fat content, glucose metabolism, insulin sensitivity 126 
BMI was calculated as weight divided by squared height. Hip circumference was measured 127 
over the buttocks; waist circumference was measured at the midpoint between the lower ribs and iliac 128 
crest.  Percentage body fat was measured by dual X-ray absorptiometry (DEXA). Abdominal visceral 129 
and subcutaneous fat areas were calculated using computed tomography (CT) scans at the level of 130 
L4–L5 in the cohort of paired visceral and subcutaneous adipose tissue donors. Three days before the 131 
OGTT, patients documented a high-carbohydrate diet in diet protocols. The OGTT was performed 132 
after an overnight fast with 75 g standardized glucose solution (Glucodex Solution 75 g; Merieux, 133 
Montreal, Canada). Venous blood samples were taken at 0, 60, and 120 min for measurements of 134 
plasma glucose concentrations. Insulin sensitivity was assessed using the HOMA-IR index or with 135 
the euglycemic-hyperinsulinemic clamp method as described previously (17). All baseline blood 136 
samples were collected between 8 and 10 am after an overnight fast. Plasma insulin, tumor necrosis 137 
factor α (TNF α) and interleukin-8 (IL-8) were measured with an enzyme immunometric assay for 138 
the IMMULITE automated analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA). 139 
Other circulating parameters including monocyte chemoattractant protein-1 (MCP-1) and progranulin 140 
were measured as previously described (9). 141 
 142 
Fas and FasL mRNA and FAS protein expression studies 143 
Human Fas and FasL mRNA expression in adipose tissue, isolated adipocytes and cells of 144 
the stromal vascular fraction was measured by quantitative real-time RT-PCR in a fluorescent 145 
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temperature cycler using the TaqMan assay, and fluorescence was detected on an ABI PRISM 7000 146 
sequence detector (Applied Biosystems, Darmstadt, Germany) as described (5, 6). Human Fas and 147 
FasL mRNA expression was calculated relative to the mRNA expression of 18S rRNA, all 148 
determined by premixed assays on demand for Fas, FasL and 18s rRNA (Applied Biosystems, 149 
Darmstadt, Germany). Fas protein expression was measured by Western blots using monoclonal anti-150 
human FAS (B-10) and normalized to glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) protein 151 
(both from Santa Cruz Biotechnology, Santa Cruz, CA). Proteins were detected by incubating with 152 
HRP conjugated secondary antibodies at a 1:3000 dilution at RT for 2 h and chemiluminescence kit 153 
(Amersham, Pharmacia, Freiburg, Germany). Integrated optical densities of the immunoreactive 154 
protein bands were measured with Gel Analyzer software (Media Cyberneties, Silver Spring, MD). 155 
Frequency of apoptotic cells was determined in histology sections of AT counting active caspase-3 156 
positive cells as described (8).  157 
 158 
Statistical analyses 159 
Data are shown as means ± SD unless stated otherwise. The following statistical tests were 160 
used: paired Student’s t-test, chi square test, and Pearson’s simple correlation. We examined 161 
independent associations between weight-loss associated changes in omental/SC Fas expression and 162 
BMI,  HbA1c, fasting plasma glucose and insulin, HOMA-IR, and circulating free fatty acids using a 163 
stepwise multivariate linear regression model stratified by gender. Statistical analysis was performed 164 
using SPSS version 12.0 (Chicago, IL). P values < 0, 05 were considered to be statistically 165 
significant. 166 
 167 
Results 168 
Fas mRNA expression correlates with parameters of obesity, adipose tissue function and 169 
insulin sensitivity 170 
Independent of gender, Fas mRNA expression in whole adipose tissue was significantly 171 
higher in omental compared to SC fat depot (Figure 1A) with a significant correlation between these 172 
two depots (r=0.22, p<0.05). Both visceral and SC Fas expression was significantly higher in 173 
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patients with obesity (Figure 1B) and T2D (Figure 1C) compared to lean or NGT controls. We found 174 
significant positive correlations between omental Fas expression and parameters of obesity including 175 
BMI (r=0.66, p<0.001), body fat (r=0.52, p<0.01), visceral fat area (r=0.66, p<0.001), and waist 176 
circumference (r=0.51, p<0.01) (Table 1). In addition, omental Fas expression significantly 177 
correlates with parameters of AT function such as adipocyte size, macrophage infiltration into 178 
visceral AT, adiponectin serum concentration (Table 2), as well as with the number of apoptotic 179 
adipocytes (r=0.64, p<0.001). Moreover, omental Fas mRNA correlates with HbA1c, circulating IL-180 
6, IL-8, MCP-1 and progranulin, but not TNFα (Table 2).  We found significant positive correlations 181 
in obese subjects between omental Fas expression and circulating triglyceride (Table 2) and FFA 182 
levels (r=0.35, p<0.01). Noteworthy, only the associations between omental Fas expression, 183 
adipocyte hypertrophy, AT macrophage infiltration and insulin sensitivity (GIR) remained significant 184 
(p<0.05) after adjusting for BMI.   185 
Subcutaneous Fas expression positively correlates with BMI, body fat, SC fat area, waist 186 
circumference, macrophage infiltration into SC AT, circulating IL-6, IL-8, MCP-1, progranulin, 187 
(Table 2), and importantly the number of apoptotic adipocytes (r=0.62, p<0.001). Both omental and 188 
SC Fas expression significantly correlate with parameters of insulin sensitivity, fasting plasma 189 
insulin, circulating adiponectin and the GIR in euglycemic-hyperinsulinemic clamps (Table 2). 190 
However, the extent of the associations between Fas expression and these parameters differs between 191 
the two fat depots. For example, the correlation between Fas (and also FasL) expression and 192 
circulating adiponectin is stronger for the omental compared to the SC fat depot (Tables 2 and 3).    193 
To further elucidate the relationship between impaired insulin sensitivity and AT Fas expression 194 
independently of BMI or fat mass, we compared Fas expression in individuals with either IS or IR 195 
obesity after strictly matching for age, gender and BMI (9). Individuals with IS obesity had 196 
significantly lower Fas expression both in omental and SC AT than IR obese individuals (Figure 197 
1D). Lower Fas expression in IS obesity is associated with significantly lower serum concentrations 198 
of IL-6, IL-8, progranulin and MCP-1 (9), which could either be the consequence or contribute to 199 
lower Fas expression in the IS compared to IR healthy obese subgroup.   200 
 201 
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We further sought to dissect the contribution of adipocytes and cells of the stromal vascular fraction 202 
(SVF) on Fas expression in adipose tissue. Expression analyses of representative subgroups (n=15 203 
per group) revealed that both isolated adipocytes and cells of the SVF contribute to differences in 204 
adipose tissue Fas expression between omental and subcutaneous fat depots, lean and obese as well 205 
as individuals with NGT or T2D (Figure 1E, F).  206 
 In parallel to Fas mRNA expression data, we found significantly higher Fas protein levels in 207 
omental compared to SC AT as well as significantly higher omental Fas protein levels in patients 208 
with obesity and type 2 diabetes compared to lean controls (Figure 1G).   209 
 210 
  211 
Reduced Fas mRNA expression after significant weight loss 212 
We aimed to analyze changes in AT Fas mRNA expression in the context of a two-step 213 
bariatric surgery strategy with an initial gastric sleeve followed by a gastric bypass surgery after ~12 214 
months. In response to bariatric surgery, we found significantly decreased BMI, improved insulin 215 
sensitivity as measured by HOMA-IR and fasting plasma insulin and reduced fasting plasma glucose, 216 
HbA1c and free fatty acids (Table 1). We found  ~40% lower omental Fas mRNA expression 12 217 
months after significant weight loss induced by the initial bariatric surgery (Figure 2A). In parallel, 218 
SC Fas mRNA expression decreased significantly by 33% (Figure 2B). By stepwise multivariate 219 
regression models stratified for gender including BMI,  HbA1c, fasting plasma glucose and insulin, 220 
HOMA-IR, and circulating free fatty acids , we identified changes in BMI as strongest predictor of 221 
decreased omental and SC Fas expression (p<0.01). 222 
 223 
FasL mRNA expression is associated with adipocyte hypertrophy and macrophage infiltration 224 
into AT 225 
In addition to Fas mRNA expression, we sought to determine FasL expression in omental 226 
and SC AT. Interestingly, FasL mRNA was only detectable in  ~60% of the AT samples (omental: 227 
n=118/196; SC: n=116/196) of the cross sectional study and in less then 50% of the IS/IR obesity 228 
subgroup (IS: omental: n=14/30; SC: n=14/30; IR: omental: n=16/30; SC: n= 14/30). Age, gender 229 
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distribution, diagnosis of type 2 diabetes, BMI, parameters of fat distribution, insulin sensitivity, 230 
adipose tissue biology, glucose or lipid metabolism were not significantly different between patients 231 
with or without detectable omental and/or SC FasL expression (data not shown).  232 
In study participants with detectable FasL expression, we find significantly higher FasL 233 
expression in omental compared to SC AT (Figure 3A). This difference was independent of gender, 234 
BMI group and the diagnosis of type 2 diabetes. FasL expression correlates between the two fat 235 
depots (r²=0.29, p<0.001). In parallel to Fas expression, both visceral and SC FasL expression was 236 
significantly higher in patients with obesity (Figure 3B) and T2D (Figure 3C) compared to lean or 237 
NGT controls. Omental FasL expression significantly correlates with BMI, % body fat, waist 238 
circumference, visceral fat area, fasting plasma insulin, GIR, circulating triglycerides, adiponectin, 239 
IL-6, IL-8, MCP-1, progranulin, adipocyte size and number of macrophages in visceral AT (Table 3). 240 
In contrast, SC FasL expression is only significantly associated with BMI, waist circumference, 241 
circulating adiponectin, adipocyte size and AT infiltrating macrophages (Table 3).  242 
The relationships between omental FasL expression, adipocyte hypertrophy, AT macrophage 243 
infiltration and insulin sensitivity (GIR) remained significant (p<0.05) after adjusting for BMI, 244 
whereas only the relationship between SC FasL mRNA and adipocyte size was independent of BMI 245 
(p<0.05). Patients with IR obesity have significantly higher FasL expression in omental, but not in 246 
SC AT than IS obese individuals (Figure 3D). To investigate the contribution of different AT cell 247 
types on FasL expression, we performed additional analyses on FasL expression in isolated 248 
adipocytes and SVF cells separately from representative subgroups (n=15 per group) of lean versus 249 
obese and NGT versus T2D in omental and SC fat. Importantly, we found in both, adipocytes and 250 
cells of the SVF, parallel differences as observed for adipose tissue as a whole (Figure 3 E, F).  251 
  252 
Discussion 253 
In this study, we find significant relationships between AT Fas expression and parameters of 254 
obesity (BMI, body fat mass), fat distribution (waist circumference, visceral and SC fat area), 255 
adipose tissue function (macrophage infiltration, adipocyte size, adiponectin serum concentration), 256 
adipocyte apoptosis and insulin sensitivity (fasting plasma insulin, clamp GIR) in humans. In adipose 257 
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tissue as a whole, but also in isolated adipocytes and cells of the SVF, Fas expression was 258 
significantly higher in omental compared to SC, in obese versus lean individuals and T2D compared 259 
to NGT patients. These data suggest that both changes in adipocyte and SVF cell Fas expression 260 
contribute to the observed group differences and correlations associated with adipose tissue Fas 261 
expression. Further studies are required to quantify the exact contribution of individual cell types 262 
within adipose tissue on altered Fas expression observed in obesity and metabolic diseases. We 263 
thereby extend previous findings in mice with an adipocyte-specific Fas- knockout (AFasKO), which 264 
are protected against HFD-induced insulin resistance (13). We demonstrate both with statistical 265 
methods and the human model system of insulin sensitive obesity (9) that associations between 266 
omental Fas expression, macrophage infiltration and insulin sensitivity are independent of BMI. Our 267 
findings thus suggest that Fas-mediated pathways in adipocytes may link adipose tissue dysfunction 268 
to impaired insulin sensitivity at the whole body level beyond simple associations between increased 269 
fat mass and insulin resistance.  270 
Increased AT Fas expression may be an important factor in the development of AT 271 
dysfunction. Fas is a proapoptotic factor, and adipocyte hypertrophy in obesity was proposed to 272 
promote adipocyte cell death, possibly with some apoptotic characteristics (18). When AT 273 
hypertrophy develops in obesity, Fas may be induced and thereby contribute to enhanced AT 274 
apoptosis, which may attract immune cells into adipose tissue. The latter may be the consequence of 275 
increased Fas-induced chemokine production as was recently shown for other cell types (19). Indeed, 276 
we found increased Fas protein levels in hypertrophic compared to small adipocytes (13). Moreover, 277 
expression of chemotactic factors such as MCP-1 was reduced in adipose tissue of AFasKO mice, as 278 
was CD11b expression, suggesting reduced immune cell attraction (13). In accordance with that, we 279 
found significant correlations between serum concentrations of the chemoattractant cytokines IL-6, 280 
IL-8, MCP-1 and progranulin and both Fas and FasL expression. However, these correlations did not 281 
remain significant after adjusting for age, gender and BMI. Thus, increased Fas expression in 282 
hypertrophic adipocytes could be an early event in the development of AT dysfunction in humans 283 
and contribute to insulin resistant obesity.  284 
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We found significant negative correlations between Fas and FasL expression and 285 
adiponectin serum concentrations, which are consistently stronger in the omental compared to SC fat 286 
depot. We included circulating adiponectin as a covariate in our study, because it has been shown 287 
that adiponectin inhibits up-regulation of Fas induced during the development of hepatic steatosis 288 
(20). Maybe due to structural similarities between the two molecules, adiponectin antagonizes many 289 
effects of TNFα and low adiponectin concentrations may contribute to increased Fas and FasL 290 
expression in obesity. Therefore, dysproportional association between adiponectin and Fas or FasL 291 
expression in the different depots may be explained by previously demonstrated lower adiponectin 292 
expression in visceral compared to SC fat depots (21).     293 
Increased apoptosis of adipocytes has been associated with obesity in both rodents and 294 
humans and may represent one of the early mechanisms causing macrophage infiltration with the 295 
subsequent development of systemic subclinical inflammation and impaired insulin sensitivity (7). In 296 
a cross-sectional study of HIV type 1-infected patients after nucleoside analogue reverse-297 
transcriptase inhibitor therapy, AT dysfunction and lipoatrophy was associated with increased 298 
apoptosis (independently of obesity) and an up to 7-fold higher number of AT macrophages 299 
compared to non-lipoatrophic HIV-1-infected patients (22). In accordance with our data, Tinahones 300 
et al. (23) recently found that a proapoptotic state characterized by increased expression of caspase 301 
3/7 and BCL2 in AT of obese humans correlates with increased immune cell infiltration into AT and 302 
impaired insulin signaling. Of course, from these cross-sectional data, it is difficult to establish a 303 
potential sequence from increased Fas expression to increased apoptosis, attraction of immune cells 304 
into AT with subsequent AT dysfunction. However, these (together with our) data are at least 305 
suggestive that activation of adipocyte apoptosis in obesity contributes to the development of insulin 306 
resistance. However, the factors protecting a subgroup of healthy insulin sensitive, but extremely 307 
obese patients (9) against such proapoptotic state need to be explored. One explanation could be that 308 
the significantly smaller adipocytes (both mean and maximal size) in insulin sensitive compared to 309 
insulin resistant obese (9) are less likely to enter apoptosis. This hypothesis is supported by data from 310 
obese mice and humans demonstrating that the frequency of apoptosis is positively correlated with 311 
increased adipocyte size (24). Moreover, >90% of macrophages in AT co-localize with dead or 312 
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apoptotic adipocytes further suggesting that apoptosis may initiate the attraction of immune cells into 313 
AT (24). Adipose tissue has a remarkable capacity to expand in a “benign” non-neoplastic manner. 314 
Increased adipocyte hypertrophy, AT dysfunction and obesity related metabolic diseases maybe the 315 
result of an impaired capacity to store even more fat (22). In many obese patients SC AT 316 
expandability is impaired, this fat depot reaches its maximal storage capacity and hypertrophied 317 
adipocytes may enter a proapoptotic state (25). Reduced Fas expression after significant weight loss 318 
upon our bariatric surgery intervention suggests that the proapoptotic state may be a reversible 319 
condition. However, since weight loss was only examined in patients following bariatric surgery, we 320 
can not exclude potential effects on adipose tissue gene expression by the surgery independently of 321 
weight loss alone.  Therefore, it would be interesting to examine changes in Fas and FasL gene 322 
expression of individuals that lost weight without surgical intervention. Further moderate weight loss 323 
interventions are required to define whether the amount of weight loss and/or predominantly visceral 324 
AT reduction may reverse increased expression of proapoptotic molecules in AT. 325 
Fas activation may also exert direct metabolic effects unrelated to cell death, similar to the 326 
endocrine effects of TNFα (26). Fas activation interfered with insulin-stimulated glucose uptake via 327 
down-regulation of Akt (14), increased secretion of pro-inflammatory cytokines (19) and enhanced 328 
lipolysis independent of apoptosis in 3T3-L1 adipocytes at least in vitro (13, 15). Supporting the 329 
latter notion, we recently reported that Fas activation increased phosphorylation of ERK1/2, and 330 
FasL-induced lipolysis was blunted in the presence of the ERK-inhibitor U0126 or in ERK1/2-331 
depleted adipocytes (15). Similarly, we show here that in obese humans subjects, omental Fas 332 
mRNA expression positively correlates with adipocyte volume and circulating FFA levels, 333 
suggesting that increased Fas expression in (hypertrophic) adipocytes may contribute to increased 334 
basal lipolysis (and hence FFA levels) in humans.  335 
In individuals with insulin sensitive obesity, factors underlying the protection against 336 
increased Fas expression despite extreme obesity need to be explored. Interestingly, correlations 337 
between FasL expression and parameters of obesity, fat distribution, AT function and glucose 338 
metabolism closely reflect the associations observed for AT Fas Expression. Similar to Fas 339 
expression, both adipocytes and cells of SVF contribute to adipose tissue FasL expression. However, 340 
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only in 50-60% of the AT donors in our study, we detected FasL mRNA expression suggesting that 341 
increased Fas expression represents an earlier detectable factor than increased FasL in the association 342 
with phenotypes like obesity, fat distribution, adipose tissue function and insulin sensitivity. 343 
 In conclusion, we show here that independently of body weight, increased Fas expression 344 
may contribute to impaired insulin sensitivity and AT dysfunction in obesity. Our data support an 345 
important role of Fas in the initiation of adipose tissue inflammation and dysfunction and suggest that 346 
reduced AT Fas expression may contribute to improved insulin sensitivity and subclinical 347 
inflammation despite obesity. 348 
 349 
 350 
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Figure legends 447 
Figure 1.  Fas mRNA expression and protein levels in human omental (OM) and subcutaneous 448 
(SC) adipose tissue.  449 
(A) Fas mRNA expression in the two different fat depots in the entire study cohort (n=256). (B) 450 
Omental (OM) and subcutaneous (SC) Fas mRNA expression in lean (BMI< 25kg/m², n=56) and 451 
obese (BMI>30kg/m², n=93) individuals. (C) Omental (OM) and subcutaneous (SC) Fas mRNA 452 
expression in normal glucose tolerant (NGT) individuals (n=129) and patients with type 2 diabetes 453 
(T2D) (n=67). (D) Omental (OM) and subcutaneous (SC) Fas mRNA expression in individuals with 454 
insulin sensitive (IS) or insulin resistant (IR) obesity. IS and IR groups were matched for age, gender, 455 
BMI and body fat mass. (E) Fas mRNA expression in isolated adipocytes from omental (OM) and 456 
subcutaneous (SC) adipose tissue of lean (BMI< 25kg/m², n=15) and obese (BMI>30kg/m², n=15), 457 
NGT (n=15) and T2D (n=15) individuals. (F) Fas mRNA expression in cells of the stromal vascular 458 
fraction (SVF) from omental (OM) and subcutaneous (SC) adipose tissue of lean (BMI< 25kg/m², 459 
n=15) and obese (BMI>30kg/m², n=15), NGT (n=15) and T2D (n=15) individuals.  460 
(G) Representative Western blots for SC and omental Fas protein level in lean, obese and T2D 461 
individuals (n=2 per group) and Fas protein levels each normalized for GAPDH protein content in 462 
SC and omental adipose tissue from lean (n=11), obese (n=9), and patients with T2D (n=7). 463 
Integrated optical densities of the immunoreactive protein bands were measured with Gel Analyzer 464 
software (Media Cyberneties, Silver Spring, MD). *p<0.05, ***p<0.001 for the difference between 465 
OM and SC fat depots. # p<0.05 for the differences between the groups. Data are means +/- SEM. 466 
*p<0.05 compared to the lean group.  467 
 468 
Figure 2.  Changes of Fas mRNA expression in response to a significant weight loss 12 months 469 
after sleeve gastrectomy surgery.  470 
(A) Omental adipose tissue Fas expression; (B) Subcutaneous adipose tissue Fas expression. Data 471 
are means +/- SEM. *p<0.05, **p<0.01 compared to baseline. 472 
 473 
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Figure 3. FasL mRNA expression in human omental and subcutaneous (SC) adipose tissue. (A) 474 
FasL mRNA expression in the two different fat depots in those study participants with detectable 475 
FasL expression (omental: n=118; SC: n=116). (B) Omental and subcutaneous (SC) FasL mRNA 476 
expression in lean (BMI< 25kg/m², n=24) and obese (BMI>30kg/m², n=62) individuals. (C) Omental 477 
and subcutaneous (SC) FasL mRNA expression in normal glucose tolerant (NGT) individuals (n=67) 478 
and patients with type 2 diabetes (T2D) (n=38). (D) Omental and subcutaneous (SC) FasL mRNA 479 
expression in individuals with insulin sensitive (IS, n=14 for both depots) or insulin resistant (IR; 480 
omental: n=16; SC: n=14) obesity. IS and IR groups were matched for age, gender, BMI and body fat 481 
mass. (E) FasL mRNA expression in isolated adipocytes from omental (OM) and subcutaneous (SC) 482 
adipose tissue of lean (BMI< 25kg/m², n=15) and obese (BMI>30kg/m², n=15), NGT (n=15) and 483 
T2D (n=15) individuals. (F) FasL mRNA expression in cells of the stromal vascular fraction (SVF) 484 
from omental (OM) and subcutaneous (SC) adipose tissue of lean (BMI< 25kg/m², n=15) and obese 485 
(BMI>30kg/m², n=15), NGT (n=15) and T2D (n=15) individuals.  486 
*p<0.05, ***p<0.001 for the difference between OM and SC fat depots. # p<0.05; ### p<0.001 for 487 
the differences between the groups. Data are means +/- SEM.  488 
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Table 1.  Effects of a sleeve gastrectomy on anthropometric and metabolic parameters 489 
at baseline and after 12±1.3 months, the time point of the second step bariatric surgery 490 
(gastric bypass). Data are expressed as mean ± SEM. *p<0.05, ** p<0.01, ***p<0.001 491 
compared to baseline. FPG, fasting plasma glucose, FPI, fasting plasma insulin, FFA, free 492 
fatty acids 493 
 494 
  
Two-step bariatric surgery intervention 
 Baseline 
Sleeve gastrectomy
12 ± 1.3 months 
Gastric bypass 
Male/female 5/11 
Age (years) 46 ±  5.8 
BMI (kg/m²) 58.9 ± 9.6 44.1 ± 6.2***  
HbA1c (%) 5.7 ± 0.2 5.2 ± 0.3* 
FPG (mmol/l) 5.8 ± 0.4  5.3 ± 0.5* 
FPI (mmol/l) 116 ± 42 47 ± 17** 
HOMA-IR 4.3 ± 0.7 1.6 ± 0.3** 
FFA (mmol/l) 0.52 ± 0.1 0.28 ± 0.07* 
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Table 2. Univariate correlations (Spearman) between Fas mRNA expression in omental 495 
and subcutaneous (SC) adipose tissue and measures of obesity, insulin sensitivity, and 496 
parameters of inflammation. GIR, glucose infusion rate during the steady state of an 497 
euglycemic-hyperinsulinemic clamp; r, Spearman´s correlation coefficient. ns, not 498 
significant 499 
 Omental Fas  
mRNA 
SC Fas  
mRNA 
 (n=196) (n=196) 
 
 
r p-value r p-value 
 
Age 0.03 ns 0.02 ns 
BMI 0.56 <0.001 0.25 <0.05 
% body fat 0.43 <0.001 0.22 <0.05 
Waist circumference 0.45 <0.001 0.37 <0.01 
Visceral fat area  0.51 <0.001 0.38 <0.01 
SC fat area 0.24 <0.05 0.35 <0.01 
Fasting plasma glucose -0.1 ns -0.09 ns 
HbA1c 0.19 0.04 0.12 ns 
Fasting plasma insulin 0.27 <0.05 0.29 <0.05 
GIR -0.34 <0.01 -0.26 <0.05 
Triglycerides 0.25 <0.05 0.24 <0.05 
Adiponectin -0.52 <0.001 -0.3 <0.01 
Mean adipocyte size 0.6 <0.001 0.34 <0.01 
IL-6  0.37 <0.01 0.37 <0.001 
IL-8 0.22 <0.05 0.18 <0.05 
MCP-1 0.31 <0.01 0.33 <0.01 
Progranulin 0.39 <0.01 0.32 <0.01 
TNFα 0.1 ns 0.12 ns 
% macophage in adipose 
tissue 
0.43 <0.001 0.33 <0.01 
 500 
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Table 3. Univariate correlations (Spearman) between FasL mRNA expression in 501 
omental and subcutaneous (SC) adipose tissue and measures of obesity, insulin 502 
sensitivity, and parameters of inflammation. GIR, glucose infusion rate during the steady 503 
state of an euglycemic-hyperinsulinemic clamp; r, Spearman´s correlation coefficient. ns, not 504 
significant 505 
 Omental FasL  
mRNA 
SC FasL 
mRNA 
  (n=118) (n=116) 
 
 
r 
 
p-value 
 
r 
 
p-value 
 
Age 0.1 ns 0.1 ns 
BMI 0.38 <0.01 0.25 <0.05 
% body fat 0.24 <0.05 0.12 ns 
Waist circumference 0.43 <0.001 0.3 <0.05 
Visceral fat area  0.63 <0.001 0.35 <0.01 
SC fat area 0.01 ns 0.17 ns 
Fasting plasma glucose -0.1 ns -0.17 ns 
HbA1c 0.2 ns -0.03 ns 
Fasting plasma insulin 0.22 <0.05 -0.05 ns 
GIR -0.47 <0.001 -0.11 ns 
Triglycerides 0.29 <0.01 0.11 ns 
Adiponectin -0.46 <0.001 -0.2 <0.05 
Mean adipocyte size 0.57 <0.001 0.41 <0.001 
IL-6  0.4 <0.001 0.18 ns 
IL-8 0.31 <0.05 0.12 ns 
MCP-1 0.25 <0.05 0.09 ns 
Progranulin 0.21 <0.05 0.08 ns 
TNFα 0.08 ns 0.06 ns 
% macophage in adipose 
tissue 
0.68 <0.001 0.2 <0.05 
 506 
 507 
 508 
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